Brief: Sosei Heptares' Partner Pfizer Progresses Its Oral Glp-1 Receptor Agonist Pf-07081532 Into Phase 2 Clinical Trials
21/12/2022 24:03
Dec 20 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES' PARTNER PFIZER PROGRESSES ITS ORAL GLP-1
RECEPTOR AGONIST PF-07081532 INTO PHASE 2 CLINICAL TRIALS FOR
TREATING TYPE 2 DIABETES AND OBESITY
* DOSING OF FIRST SUBJECT IN PHASE 2 TRIAL BY PFIZER
TRIGGERS
PAYMENT OF US$10 MILLION TO SOSEI HEPTARES
Source text for Eikon: ID:nGNX9vFfBL
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up